Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Imiquimod and TA-CIN Vaccination for High Grade VIN3
2005-001824-35Phase 2Completed
- Sponsor
- The University of Manchester
- Start
- Nov 2005
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod and TA-CIN in vulvar intraepithelial neoplasia (VIN) and anal intraepithelial neoplasia (AIN), sponsored by The University of Manchester. Primary endpoint: Lesion size at 12 months post treatment. Started Nov 2005; status: completed.
02
Drugs
imiquimodTA-CIN
03
Conditions
vulvar intraepithelial neoplasia (VIN)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on 2005-001824-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001824-35.